Phathom Pharmaceuticals to Attend Investor Conferences in April 2026

The biopharmaceutical company will participate in one-on-one meetings and a fireside chat at upcoming events.

Apr. 6, 2026 at 1:43pm

Got story updates? Submit your updates here. ›

Phathom Pharmaceuticals, a biopharmaceutical company focused on gastrointestinal (GI) diseases, announced that members of its management team will participate in upcoming investor conferences in April 2026, including the Raymond James 2026 Biotech Innovation Symposium and the 25th Annual Needham Virtual Healthcare Conference. The company will take part in one-on-one meetings and a fireside chat to discuss its business and product portfolio.

Why it matters

Phathom's participation in these high-profile investor conferences demonstrates the company's commitment to engaging with the financial community and providing updates on its progress in commercializing and developing novel GI treatments, including its flagship product VOQUEZNA.

The details

At the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026, Phathom's management team will participate in one-on-one meetings throughout the conference. On April 15, 2026, the company will take part in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, in addition to holding one-on-one meetings.

  • Phathom Pharmaceuticals will participate in the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14, 2026.
  • Phathom Pharmaceuticals will participate in the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026.

The players

Phathom Pharmaceuticals, Inc.

A biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases, including VOQUEZNA, its flagship product.

Got photos? Submit your photos here. ›

What’s next

Investors and the public will be able to access the live webcast and archived recording of Phathom's fireside chat at the 25th Annual Needham Virtual Healthcare Conference on the company's website.

The takeaway

Phathom Pharmaceuticals' participation in these high-profile investor conferences underscores the company's commitment to engaging with the financial community and providing updates on its progress in commercializing and developing novel treatments for gastrointestinal diseases.